IXAZOMIB

IXAZOMIB

Capsules

NINLARO (ixazomib) is an antineoplastic agent. NINLARO (ixazomib) capsules for oral use contain 4, 3 or 2.3 mg of ixazomib equivalent to 5.7, 4.3 or 3.3 mg of ixazomib citrate, respectively. Inactive ingredients include microcrystalline cellulose, magnesium stearate, and talc. Capsule shells contain gelatin and titanium dioxide. The 4 mg capsule shell contains red and yellow iron oxide, the 3 mg capsule shell contains black iron oxide and the 2.3 mg capsule shell contains red iron oxide. The printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.
NINLARO (ixazomib) Capsules: 4 mg, 3 mg, and 2.3 mg
Recommended starting dosage of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle.
NINLARO (ixazomib) is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.